A Philadel­phia-based CD­MO will drop $100 mil­lion in­to its asep­tic liq­uid fill-fin­ish and ster­ile lyophiliza­tion tech­nol­o­gy at its re­cent­ly-ac­quired Bed­ford, NH cam­pus.

PCI Phar­ma bought the Lyophiliza­tion Ser­vices of that New Eng­land site at the end of 2021. The new ex­pan­sion will add a 50,000 square-foot fa­cil­i­ty that fea­tures a fill-fin­ish line with a ful­ly iso­lat­ed con­tain­ment sys­tem. It will have the ca­pac­i­ty to fill 400 vials per minute, which will help PCI up its speed and get ther­a­pies to pa­tients quick­er.

The an­nounce­ment is the lat­est in a string of moves across the world. It has ex­pand­ed lo­ca­tions in Rock­ford, IL; San Diego; Mel­bourne, Aus­tralia and Berlin in re­cent years. The com­pa­ny will al­so in­crease ca­pac­i­ty at sites in Spain and Wis­con­sin soon, the press re­lease said.

“We are ex­cit­ed to in­tro­duce clients to our newest fa­cil­i­ty, which is part of our broad­er strat­e­gy to pro­vide in­te­grat­ed end-to-end drug de­vel­op­ment, man­u­fac­tur­ing and pack­ag­ing ca­pa­bil­i­ties,” CEO Sal­im Haf­far said in a state­ment. “Our in­vest­ment in these fa­cil­i­ties will en­sure that PCI con­tin­ues to lever­age new ca­pa­bil­i­ties in com­plex for­mu­la­tions, asep­tic fill-fin­ish, and lyophiliza­tion to meet the needs of our glob­al clients, par­tic­u­lar­ly as bi­o­log­ics con­tin­ue their strong growth tra­jec­to­ry.”

Just in No­vem­ber 2021, PCI an­nounced the con­struc­tion of a new clin­i­cal cen­ter of ex­cel­lence in Bridge­wa­ter, MA, just 25 miles south of Boston. The in­vest­ment al­lows for PCI to be clos­er to clients in the tri-state area, as well as just down the high­way from some of the biggest phar­mas in the world. That cen­ter is sched­uled to be com­plet­ed this sum­mer, and will al­so add 50,000 square feet of op­er­at­ing space to its ar­se­nal.

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu scored its second approval in less than a week, this time for a subset of lung cancer patients.

Enhertu received accelerated approval on Thursday to treat adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have already received a prior systemic therapy.

After controversially spinning out its talc liabilities and filing for bankruptcy in an attempt to settle 38,000 lawsuits, Johnson & Johnson is now changing up the formula for its baby powder products.

J&J is beginning the transition to an all cornstarch-based baby powder portfolio, the pharma giant announced on Thursday — just months after a federal judge ruled in favor of its “Texas two-step” bankruptcy to settle allegations that its talc products contained asbestos and caused cancer. An appeals court has since agreed to revisit that case.

As Ireland continues to see more investments and building projects from pharma companies, another contender is looking to place more investment in the Emerald Isle.

According to a report from The Irish Times on Friday, Abbott Laboratories is investing €440 million, or about $451 million, to build a new manufacturing plant in Kilkenny, located in the country’s southeast, to make more of its glucose monitors.